One of the Best Cannabis Company Stocks to Buy for Massive Returns

Over the last decade, 11 states have legalized marijuana. That's created a $10.4 billion industry. And it's minted millionaires overnight.

But there are billions more up for grabs. And one of our best cannabis company stocks could create the next class of millionaires.

Meticulous Research says the global cannabis market is projected to grow by 28.3% over the next six years.

That's a $75.6 billion market by 2025.

But there are hundreds of cannabis stocks out there. And most of them don't have strong financials. It can be difficult to find a winner right now.

That's why we rely on a secret weapon: the Money Morning Stock VQScore™ system.

The proprietary VQScore system evaluates stocks based on their real profit potential. A higher score means greater profit potential.

THREE STOCKS: Any one of these cannabis companies could potentially deliver a 1,000% windfall. Click here to learn more...

Most cannabis stocks don't currently have the strong underlying financials to generate a high VQScore. But our system has recently identified a cannabis company stock poised to skyrocket.

In fact, it has our highest VQScore of 4.9. That means it's almost certain to ride the market growth from future cannabis legalization.

This is also the highest VQScore of any cannabis company stock we've ever seen.

And it's trading at a huge bargain right now...

This Cannabis Company Stock Is Sitting Right Under Wall Street's Nose

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Cronos Group Inc. (NASDAQ: CRON) is a little-known global cannabinoid company.

Since February 2018, prices have fallen nearly 50% in the face of increasing scrutiny over vaping products and their association with acute lung illness.

While the news spooked investors, most shareholders are missing the bigger picture.

You see, most of the hysteria over vaping stems from the misuse of black market marijuana products in states that have yet to legalize cannabis.

In other words, the crisis isn't a result of a problem in the cannabis industry - it's a temporary blowback. But it's likely to subside as states legalize cannabis and allow consumers to buy marijuana through regulated channels.

All Cronos has to do is weather the storm. Luckily, it has just the strategy to do that.

Cronos Is Breaking Away from the Herd

Cronos has an innovative approach to raising capital that sets it apart from most cannabis companies.

Rather than trying to do this through repeated share offerings, the firm goes after cash deals with other firms.

In March, Cronos closed a $1.8 billion cash deal with Altria Group Inc. (NYSE: MO) for a 45% stake in the company.

Private investment allows Cronos to preserve the value of the shares on the market. That gives shareholders more incentive to hang on to their shares.

It also allows the firm to make strategic acquisitions and develop a strong market position against competitors.

Cronos also doesn't attempt to directly compete with other cannabis firms. Their focus is on cannabinoid (CBD) products rather than run-of-the-mill marijuana cultivation.

The company sees that directly growing cannabis will be less profitable as market competition grows. That's why Cronos has thrown its weight into producing high-margin CBD products with mass market appeal and less competition.

So far, the strategy has more than paid off.

In the last two quarters of 2019 alone, the firm has recorded a gross profit of CA$510 million.

That's a 120% increase in returns year over year. And it's only going to get better.

Analysts estimate the firm is on track to generate CA$60.1 million in revenue this year - a 283% increase over 2018.

And that estimate may even be lowballing the company's real profit potential.

Just last week, Cronos inked a deal with MediPharm Labs Corp. (OTC: MEDIF) to develop regulated vaping products with Cronos' COVE line of CBD products.

According to Cronos CEO Mike Gorenstein, the partnership is aimed at expanding Cronos' market share and global availability.

"We are committed to continuing to the lead the industry responsibly as derivative products are introduced to the expanding Canadian marketplace," he said.

No wonder the company currently has the highest possible VQScore of 4.9.

You can currently pick up shares of Cronos for as little as $13.60. But analysts expect shares to jump as much as 83% by the end of 2020.

Shhh... Cannabis Sector Secrets Herein: Wall Street doesn't want you to know this, but... not all cannabis stocks are champs. All pot stocks see highs and lows, but some are just... flops. Don't worry; we've picked what we believe are the "winners from the wannabes." Just click here to get them.

Follow Money Morning on Facebook and Twitter.